Gabelli & Co Investment Advisers’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-113,650	Closed	-$8.55M	–	516
2022 Q2	$8.55M	Buy	+113,650	New	+$5.05M	1.1%	28

Gabelli & Co Investment Advisers's TPTX Position: Q3 2022 in Review

Gabelli & Co Investment Advisers sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 113,650 shares — an estimated $8.55M sold.

Gabelli & Co Investment Advisers first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $8.55M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Gabelli & Co Investment Advisers reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 113,650 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $8.55M.
Gabelli & Co Investment Advisers first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Turning Point Therapeutics, Inc. Common Stock position peaked at $8.55M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2022, filed 10 Nov 2022.